Key result
This review examines the effects of the angiotensin receptor blocker irbesartan on restoring physiological endothelial function beyond its antihypertensive action.
Why the study?
Does irbesartan improve endothelial function beyond its antihypertensive effects?
Does irbesartan improve endothelial function beyond its antihypertensive effects?
This review highlights the potential of irbesartan and other RAS blockers to improve endothelial dysfunction, a key contributor to atherosclerosis and cardiovascular risk, independent of blood pressure lowering.
Irbesartan may improve endothelial function beyond BP lowering; leaves open confirmation in outcome trials before practice change.
The endothelium is characterized by a wide range of important homeostatic functions. It participates in the control of hemostasis, blood coagulation and fi brinolysis, platelet and leukocyte interactions with the vessel wall, regulation of vascular tone, and of blood pressure. Many crucial vasoactive endogenous compounds are produced by the endothelial cells to control the functions of vascular smooth muscle cells and of circulating blood cells. These complex systems determine a fi ne equilibrium which regulates the vascular tone. Impairments in endotheliumdependent vasodilation lead to the so called endothelial dysfunction. Endothelial dysfunction is then characterized by unbalanced concentrations of vasodilating and vasoconstricting factors, the most important being represented by nitric oxide (NO) and angiotensin II (AT II). High angiotensin-converting enzyme (ACE) activity leads to increased AT II generation, reduced NO levels with subsequent vasoconstriction. The net acute effect results in contraction of vascular smooth muscle cells and reduced lumen diameter. Furthermore, when increased ACE activity is chronically sustained, increase in growth, proliferation and differentiation of the vascular smooth muscle cells takes place; at the same time, a decrease in the anti-proliferative action by NO, a decrease in fi binolysis and an increase in platelets aggregation may be observed. AT II is then involved not only in the regulation of blood pressure, but also in vascular infl ammation, permeability, smooth muscle cells remodelling, and oxidative stress which in turn lead to atherosclerosis and increased cardiovascular risk. Given the pivotal role exerted by AT II in contributing to alteration of endothelial function, treatment with ACE inhibitors or angiotensin receptor blockers (ARBs) may be of particular interest to restore a physiological activity of endothelial cells. In this view, the blockade of the renin-angiotensin system (RAS), has been shown to positively affect the endothelial function, beyond the antihypertensive action displayed by these compounds. In this review, attention has been specifi cally focused on an ARB, irbesartan, to examine its effects on endothelial function.
No takes yet. Share an insight, caveat, or question.
Roberto W. Dal Negro (2008) conducted a review in Endothelial dysfunction and hypertension. Irbesartan was evaluated. This review examines the effects of the angiotensin receptor blocker irbesartan on restoring physiological endothelial function beyond its antihypertensive action.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: